XML 20 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue      
Total revenue $ 907,957,000 $ 924,639,000 $ 687,122,000
Expenses      
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) [1] 657,551,000 696,581,000 513,033,000
Selling, general and administrative expenses [1] 219,499,000 210,412,000 236,448,000
Depreciation and amortization expenses 60,037,000 60,835,000 60,323,000
Loss (gain) on disposal of assets and consolidation 0 698,000 (9,600,000)
Loss on extinguishment of debt, net 0 4,789,000 0
Goodwill impairment 0 215,100,000 199,800,000
Change in fair value of contingent consideration and indemnification asset 13,281,000 3,860,000 (3,997,000)
Total operating expenses 950,368,000 1,192,275,000 996,007,000
Operating loss (42,411,000) (267,636,000) (308,885,000)
Interest income 407,000 2,633,000 3,406,000
Interest expense (25,425,000) (28,325,000) (14,555,000)
Impairment of equity method investments 0 (47,133,000) 0
Gain (loss) from equity method investees 13,179,000 10,039,000 (9,465,000)
Gain on transfer of membership 45,938,000 0 0
Loss on repayment of debt (21,343,000) 0 0
Other expense, net (146,000) (118,000) (489,000)
Loss from continuing operations before income taxes (29,801,000) (330,540,000) (329,988,000)
Provision (benefit) for income taxes 483,000 (2,368,000) (22,795,000)
Loss from continuing operations (30,284,000) (328,172,000) (307,193,000)
Income (loss) from discontinued operations, net of tax [2] (7,317,000) (6,074,000) 1,613,000
Net loss (37,601,000) (334,246,000) (305,580,000)
Net loss attributable to non-controlling interests 0 0 (3,609,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - Basic (37,601,000) (334,246,000) (301,971,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted $ (37,601,000) $ (334,246,000) $ (301,971,000)
Loss per common share      
Continuing operations, basic (in dollars per share) $ (0.35) $ (3.86) $ (3.73)
Continuing operations, diluted (in dollars per share) (0.35) (3.86) (3.73)
Discontinued operations, basic (in dollars per share) (0.09) (0.08) 0.02
Discontinued operations, diluted (in dollars per share) (0.09) (0.08) 0.02
Non-controlling interests, basic (in dollars per share) 0 0 0.04
Non-controlling interests, diluted (in dollars per share) 0 0 0.04
Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) (0.44) (3.94) (3.67)
Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) $ (0.44) $ (3.94) $ (3.67)
Weighted-average common shares outstanding      
Basic (in shares) 86,067 84,928 82,364
Diluted (in shares) 86,067 84,928 82,364
Comprehensive loss      
Net loss $ (37,601,000) $ (334,246,000) $ (305,580,000)
Other comprehensive loss, net of taxes, related to:      
Foreign currency translation adjustment (84,000) (44,000) (52,000)
Total comprehensive loss (37,685,000) (334,290,000) (305,632,000)
Total comprehensive loss attributable to non-controlling interests 0 0 (3,609,000)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. (37,685,000) (334,290,000) (302,023,000)
Transformation services      
Revenue      
Total revenue [1] 11,204,000 11,990,000 15,203,000
Platform and operations services      
Revenue      
Total revenue [1] $ 896,753,000 $ 912,649,000 $ 671,919,000
[1] See Note 20 for amounts attributable to unconsolidated related parties included in these line items.
[2] Includes $6.8 million loss on disposal of discontinued operations for the year ended December 31, 2021